Post-authorization Safety Study of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Treated With Mogamulizumab
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorKyowa Kirin, Inc.
About this trial
This is a non-interventional cohort study evaluating non-relapse mortality and toxicities in patients with CTCL or ATLL treated with mogamulizumab pre- or post- alloHCT for patients transplanted beginning January 1, 2012 until accrual is complete.
Eligibility criteria
Qualifiers
Patients registered to the Center for International Blood and Marrow Transplant Research (CIBMTR)
Adults ≥18 years of age with either CTCL or ATLL;
AlloHCT performed from January 2012 onward.
Disqualifiers
None
Trial design
Treatments tested in this trial
- Not listed
Trial groups
150 Participants
are grouped into 2 trial groupsSponsors and collaborators
Source ClinicalTrials.gov